COMPANY
Tasso, Inc
Timeline
- Trial start —: Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer source ↗
- Partnership Partnership / licensing announced Feb 3, 2025. Source: company's own press page. source ↗
- Trial start —: A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC source ↗
- Trial start —: A Multi-site Clinical Evaluation of Capillary Blood Samples Collected Using the Tasso+SST Device for Downstream Analyte Testing source ↗
- Trial start —: ALT Routinely Recorded Remotely: A Comparator Study of Liver Function Tests Using the Tasso+ to Venipuncture. source ↗
Upcoming milestones
- Oct 31, 2026 (ESTIMATED) · · Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer · NCT07260799
Funding
- Partnership / licensing announced Feb 3, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07260799 | Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer | Not listed | Active, not recruiting | Oct 25, 2025 | Oct 31, 2026 (estimated) |
| NCT06392269 | A Multi-site Clinical Evaluation of Capillary Blood Samples Collected Using the Tasso+SST Device for Downstream Analyte Testing | Not listed | Completed | Mar 18, 2024 | Apr 15, 2025 (actual) |
| NCT06360952 | A Comparator Study of a Tasso Device Blood Sample to Traditional Venous Blood Sample for CBC | Not listed | Unknown status (ClinicalTrials.gov) | May 31, 2024 | Aug 31, 2024 (estimated) |
| NCT05259618 | ALT Routinely Recorded Remotely: A Comparator Study of Liver Function Tests Using the Tasso+ to Venipuncture. | Not listed | Unknown status (ClinicalTrials.gov) | Feb 16, 2021 | 2022-11 (estimated) |
NIH awards 7
- NIH award 3R43CA221612-01A1S1 FY2018: $15,000 awarded for that fiscal year; activity R43 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. Patient-centered leukemia diagnostic and monitoring source ↗
- NIH award 1R43CA221612-01A1 FY2017: $230,436 awarded for that fiscal year; activity R43 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. Patient-centered leukemia diagnostic and monitoring source ↗
- NIH award 5R44DK108689-02 FY2016: $488,112 awarded for that fiscal year; activity R44 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. Paired genomics and proteomics point-of-care platform source ↗
- NIH award 1R43AI122474-01 FY2016: $220,000 awarded for that fiscal year; activity R43 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. Integrated sample collection-to-preparation platform f source ↗
- NIH award 1R44DK108689-01 FY2015: $497,674 awarded for that fiscal year; activity R44 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. Paired genomics and proteomics point-of-care platform source ↗
- NIH award 5R43MD008596-02 FY2014: $200,000 awarded for that fiscal year; activity R43 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. An integrated platform for blood collection, HIV viral source ↗
- NIH award 1R43MD008596-01 FY2013: $196,601 awarded for that fiscal year; activity R43 (SBIR); PI BERTHIER, ERWIN; recipient as written: TASSO, INC., SEATTLE, WA. An integrated platform for blood collection, HIV viral source ↗